The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Co. (LLY), GE Aerospace ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...

Over the past six months, Eli Lilly has earned significant wins over its Denmark-based rival and is still at it. Recent clinical trial results Eli Lilly released suggest that it is building a lead in ...

Eli Lilly (LLY) stock in focus as the company beats Biogen (BIIB) to win regulatory nod in Australia for first ...

HSBC has once again reduced its price target for Eli Lilly, this time dropping it to $675 from $700 while maintaining a ...

Drugmaker Eli Lilly and Company has hired Sandy Rodriguez as SVP and chief communications officer, effective on June 9. Rodriguez will report to Jennifer Oleksiw, SVP and global chief customer officer ...

As Eli Lilly and Novo Nordisk continue to go in opposite directions in their diabetes and obesity market rivalry, so too have ...

Global pharmaceutical giant Eli Lilly & Co. is seeking tax incentives for a potential 236-acre biomanufacturing plant in ...

The U.S. FDA cleared Novavax Inc.’s COVID-19 vaccine Nuvaxovid for adults 65 and over and people 12-64 years old with at least one underlying condition that puts them at risk of severe outcomes from ...

With $27 billion earmarked to expand its U.S. production footprint starting this year, Eli Lilly is busy scouting out ...

Eli Lilly is turning up the volume on gene therapy with a $1.3 billion partnership with Rznomics to tackle sensorineural ...

Eli Lilly and Company (NYSE:LLY) announced a partnership with Rznomics to develop RNA-based gene therapies for sensorineural ...